Rubius Therapeutics analyst ratings
Rubius Therapeutics analyst ratings
While ratings are subjective and will change, the latest Rubius Therapeutics (RUBY) rating was a maintained with a price target of $2.00 to $1.00. The current price Rubius Therapeutics (RUBY) is trading at is $0.81, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2022 | 22.77% | SVB Leerink | $2 → $1 | Maintains | Market Perform |
| 05/11/2022 | 145.55% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 05/11/2022 | 882.2% | HC Wainwright & Co. | $15 → $8 | Maintains | Buy |
| 05/10/2022 | 268.32% | SVB Leerink | $2 → $3 | Maintains | Market Perform |
| 04/11/2022 | 391.1% | Morgan Stanley | $15 → $4 | Maintains | Equal-Weight |
| 04/11/2022 | 513.87% | Guggenheim | $25 → $5 | Maintains | Buy |
| 04/11/2022 | 1741.62% | HC Wainwright & Co. | $40 → $15 | Maintains | Buy |
| 04/11/2022 | 268.32% | SVB Leerink | $5 → $3 | Maintains | Market Perform |
| 02/25/2022 | 513.87% | SVB Leerink | $14 → $5 | Maintains | Market Perform |
| 11/09/2021 | 1618.85% | SVB Leerink | $20 → $14 | Maintains | Market Perform |
| 05/18/2021 | 2969.37% | Morgan Stanley | $24 → $25 | Maintains | Equal-Weight |
| 04/19/2021 | 2846.59% | Morgan Stanley | $10 → $24 | Maintains | Equal-Weight |
| 03/15/2021 | 2355.49% | SVB Leerink | $4 → $20 | Maintains | Market Perform |
| 03/15/2021 | 4810.99% | HC Wainwright & Co. | $28 → $40 | Maintains | Buy |
| 02/23/2021 | 391.1% | SVB Leerink | $5 → $4 | Maintains | Market Perform |
| 01/19/2021 | 1127.75% | Morgan Stanley | $5 → $10 | Maintains | Equal-Weight |
| 11/11/2020 | 513.87% | Morgan Stanley | $4 → $5 | Maintains | Equal-Weight |
| 03/13/2020 | 391.1% | Morgan Stanley | $15 → $4 | Downgrades | Overweight → Equal-Weight |
| 03/13/2020 | 3337.69% | HC Wainwright & Co. | $40 → $28 | Maintains | Buy |
| 11/15/2019 | 2109.94% | JP Morgan | $22 → $18 | Maintains | Overweight |
| 11/15/2019 | 1741.62% | Morgan Stanley | $17 → $15 | Maintains | Overweight |
| 09/10/2019 | 391.1% | Baird | → $4 | Initiates Coverage On | → Underperform |
| 08/29/2019 | 2601.04% | JP Morgan | $27 → $22 | Maintains | Overweight |
| 06/26/2019 | 4810.99% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 05/31/2019 | 2969.37% | Guggenheim | → $25 | Initiates Coverage On | → Buy |
| 12/19/2018 | 4074.34% | Morgan Stanley | $37 → $34 | Maintains | Overweight |
| 08/13/2018 | 3583.24% | Leerink Swann | → $30 | Initiates Coverage On | → Outperform |
| 08/13/2018 | — | JP Morgan | Initiates Coverage On | → Overweight | |
| 08/13/2018 | 4442.66% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 08/13/2018 | 4810.99% | Jefferies | → $40 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2022 | 22.77% | SVB Leerink | $2 → $1 | 維護 | 市場表現 |
| 05/11/2022 | 145.55% | 摩根士丹利 | $4 → $2 | 維護 | 等重 |
| 05/11/2022 | 882.2% | HC Wainwright公司 | $15 → $8 | 維護 | 買 |
| 05/10/2022 | 268.32% | SVB Leerink | $2 → $3 | 維護 | 市場表現 |
| 04/11/2022 | 391.1% | 摩根士丹利 | $15 → $4 | 維護 | 等重 |
| 04/11/2022 | 513.87% | 古根海姆 | $25 → $5 | 維護 | 買 |
| 04/11/2022 | 1741.62% | HC Wainwright公司 | $40 → $15 | 維護 | 買 |
| 04/11/2022 | 268.32% | SVB Leerink | $5 → $3 | 維護 | 市場表現 |
| 02/25/2022 | 513.87% | SVB Leerink | $14 → $5 | 維護 | 市場表現 |
| 11/09/2021 | 1618.85% | SVB Leerink | $20 → $14 | 維護 | 市場表現 |
| 05/18/2021 | 2969.37% | 摩根士丹利 | $24 → $25 | 維護 | 等重 |
| 04/19/2021 | 2846.59% | 摩根士丹利 | $10 → $24 | 維護 | 等重 |
| 03/15/2021 | 2355.49% | SVB Leerink | $4 → $20 | 維護 | 市場表現 |
| 03/15/2021 | 4810.99% | HC Wainwright公司 | $28 → $40 | 維護 | 買 |
| 02/23/2021 | 391.1% | SVB Leerink | $5 → $4 | 維護 | 市場表現 |
| 01/19/2021 | 1127.75% | 摩根士丹利 | $5 → $10 | 維護 | 等重 |
| 11/11/2020 | 513.87% | 摩根士丹利 | $4 → $5 | 維護 | 等重 |
| 03/13/2020 | 391.1% | 摩根士丹利 | $15 → $4 | 評級下調 | 超重→等重 |
| 03/13/2020 | 3337.69% | HC Wainwright公司 | $40 → $28 | 維護 | 買 |
| 11/15/2019 | 2109.94% | 摩根大通 | $22 → $18 | 維護 | 超重 |
| 11/15/2019 | 1741.62% | 摩根士丹利 | $17 → $15 | 維護 | 超重 |
| 09/10/2019 | 391.1% | 貝爾德 | → $4 | 開始承保 | →表現不佳 |
| 08/29/2019 | 2601.04% | 摩根大通 | $27 → $22 | 維護 | 超重 |
| 06/26/2019 | 4810.99% | HC Wainwright公司 | → $40 | 開始承保 | →購買 |
| 05/31/2019 | 2969.37% | 古根海姆 | → $25 | 開始承保 | →購買 |
| 12/19/2018 | 4074.34% | 摩根士丹利 | $37 → $34 | 維護 | 超重 |
| 08/13/2018 | 3583.24% | 利林克·斯旺 | → $30 | 開始承保 | →跑贏大盤 |
| 08/13/2018 | — | 摩根大通 | 開始承保 | →超重 | |
| 08/13/2018 | 4442.66% | 摩根士丹利 | → $37 | 開始承保 | →超重 |
| 08/13/2018 | 4810.99% | 傑富瑞 | → $40 | 開始承保 | →購買 |
Rubius Therapeutics Questions & Answers
Rubius Treateutics問答
The latest price target for Rubius Therapeutics (NASDAQ: RUBY) was reported by SVB Leerink on August 9, 2022. The analyst firm set a price target for $1.00 expecting RUBY to rise to within 12 months (a possible 22.77% upside). 10 analyst firms have reported ratings in the last year.
Rubius治療公司(納斯達克：RUBY)的最新目標價是由SVB Leerink於2022年8月9日報道的。這家分析公司將目標價定為1.00美元，預計Ruby將在12個月內上漲(可能上漲22.77%)。去年有10家分析公司公佈了評級。
The latest analyst rating for Rubius Therapeutics (NASDAQ: RUBY) was provided by SVB Leerink, and Rubius Therapeutics maintained their market perform rating.
Rubius治療公司(納斯達克代碼：RUBY)的最新分析師評級由SVB Leerink提供，Rubius治療公司維持其市場表現評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rubius Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rubius Therapeutics was filed on August 9, 2022 so you should expect the next rating to be made available sometime around August 9, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Rubius Treeutics的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Rubius治療公司的上一次評級是在2022年8月9日提交的，所以你應該預計下一次評級將在2023年8月9日左右提供。
While ratings are subjective and will change, the latest Rubius Therapeutics (RUBY) rating was a maintained with a price target of $2.00 to $1.00. The current price Rubius Therapeutics (RUBY) is trading at is $0.81, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Rubius Treeutics(Ruby)評級保持不變，目標價在2.00美元至1.00美元之間。Rubius Treateutics(Ruby)目前的交易價格為0.81美元，超出了分析師的預測區間。
